Overview

12- Week Open Label Treatment of Refractory Bipolar Depression

Status:
Completed
Trial end date:
2009-09-01
Target enrollment:
Participant gender:
Summary
1. Determine the change in symptomatology and function in refractory bipolar depression, when treated with combination of DEP+AZP for a period of 12 weeks 2. Determine the tolerability and safety of AZP added to DEP in the treatment of refractory bipolar depression
Phase:
Phase 4
Details
Lead Sponsor:
The University of Texas Health Science Center at San Antonio
Collaborator:
Bristol-Myers Squibb
Treatments:
Aripiprazole